ENTITY
Abbisko Cayman

Abbisko Cayman (2256 HK)

23
Analysis
Health Care • China
Abbisko Cayman Limited operates as a biopharmaceutical company. The Company dedicated to the discovery and development of innovative and differentiated small molecule incology therapies. Abbisko Cayman provides services in China.
more
bearish•Gushengtang
•09 Dec 2021 14:46

Gushengtang IPO Trading - Priced at Top End with Lukewarm Subscription Rates

Gushengtang (GUS HK) raised around US$104m after pricing its IPO at HKD29.0/share, at the top end of the IPO price range.

Logo
513 Views
Share
bullish•GQG Partners
•17 Oct 2021 10:27

ECM Weekly (17th October 2021) - SG Lottery, GQG, Judo Bank, Vulcan Steel, Biocytogen, Kakao Pay

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Logo
542 Views
Share
bearish•Abbisko Cayman
•12 Oct 2021 11:25

Abbisko (å’ŒčŖ‰) IPO Trading: Poor Demand for the Early Stage R&D

We provide an update of Abbisko prior to the trading and re-iterate our view that the company is fairly valued for the early stage despite...

Logo
320 Views
Share
•06 Oct 2021 09:02

Pre-IPO TransThera Sciences (Nanjing) - Insights on the Industry, the Business and the Concerns

This article mainly analyzed TransThera in terms of theĀ industry characteristics of small molecule drug market, candidates in the pipeline (TT...

Logo
398 Views
Share
bearish•Abbisko Cayman
•30 Sep 2021 15:44

Abbisko IPO: Valuation Insights

Abbisko plans to raise $204m (net) at the mid-point of the IPO price range. Our valuation analysis suggests that the IPO price range is full and we...

Logo
407 Views
Share
x